In a filing, U.S. Physical Therapy, Inc revealed its Director HAM NANCY unloaded Company’s shares for reported $31204.0 on Jun 12 ’25. In the deal valued at $78.01 per share,400 shares were sold. As a result of this transaction, HAM NANCY now holds 2,594 shares worth roughly $0.19 million.
Then, HAM NANCY bought 400 shares, generating $31,430 in total proceeds.
Before that, REEVE GRAHAM D. sold 530 shares. U.S. Physical Therapy, Inc shares valued at $41,382 were divested by the COO at a price of $78.08 per share. As a result of the transaction, REEVE GRAHAM D. now holds 17,244 shares, worth roughly $1.28 million.
BofA Securities upgraded its U.S. Physical Therapy, Inc [USPH] rating to a Buy from a a Neutral in a research note published on December 16, 2024; the price target was increased to $115 from $100. A number of analysts have revised their coverage, including JMP Securities’s analysts, who began to cover the stock in mid December with a ‘”a Mkt outperform”‘ rating. BofA Securities also remained covering USPH and has decreased its forecast on October 07, 2024 with a “Neutral” recommendation from previously “Buy” rating. JP Morgan started covering the stock on September 22, 2023. It rated USPH as “an Overweight”.
Price Performance Review of USPH
On Tuesday, U.S. Physical Therapy, Inc [NYSE:USPH] saw its stock fall -3.74% to $74.45. Over the last five days, the stock has lost -5.76%. U.S. Physical Therapy, Inc shares have fallen nearly -16.07% since the year began. Nevertheless, the stocks have fallen -21.38% over the past one year. While a 52-week high of $101.19 was reached on 01/23/25, a 52-week low of $62.77 was recorded on 04/07/25.
Levels Of Support And Resistance For USPH Stock
The 24-hour chart illustrates a support level at 73.48, which if violated will result in even more drops to 72.50. On the upside, there is a resistance level at 76.33. A further resistance level may holdings at 78.21.
The most recent change occurred on June 30, 2023 when BofA Securities began covering the stock and recommended ‘”a Buy”‘ rating along with a $138 price target.
